Asthma Management: New Developments- Pharmacist

  Price  $6.95

  Credits  1.5

Clear


Format
Asthma is a chronic inflammatory disease that affects over 339 million individuals worldwide. Characterized by variable airflow limitation and bronchial hyperresponsiveness, symptoms include wheezing, shortness of breath, chest tightness, and/or cough. Asthma symptoms are episodic in nature, often worse at night or in the early morning, and can be triggered by factors such as exercise, airborne allergens, pollution, cigarette smoking, weather changes (eg, very cold, low humidity), and viral upper respiratory infections. To diagnose asthma, patients must have a history of variable respiratory symptoms, as well as limited expiratory airflow that has been confirmed with spirometry. The long-term goals of asthma management are to achieve good symptom control that enables patients to maintain normal activity levels, to minimize persistent airflow limitation, side effects from treatment, and asthma-related exacerbations, and to prevent asthma-related death...
$6.95

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Pharmacist

Author

Jessica Wallace
PharmD, BCPS
Jonathan Hughes
PharmD, BCPS, BCACP
Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

  • Discuss the current GINA recommendations for stepwise treatment of asthma, including the role for SABA, LABA, and inhaled corticosteroids (ICS). Recognize ICS-LABA combination products approved for the treatment of asthma and their age-specific daily doses.
  • Discuss the reasons and possible solutions for poor asthma medication adherence. Provide 2 examples of personalized controller therapy that may not be consistent with general treatment recommendations in clinical practice guidelines.
  • Describe the rationale for the use of biologics in patients with severe asthma uncontrolled by ICS and bronchodilator therapy. List approved agents, dosing, and potentially serious side effects.

Course Accreditation

  • Activity Type:
    Knowledge
  • CE Broker
    20-878270
  • Universal Activity Number:
    Pharmacist : 0798-0000-21-197-H01-P
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.